Background: Patients with schizophrenia are often markedly impaired in their social functioning, partly independent of symptom severity. Few studies have examined patients’ self-reporting of their social functioning, how a patient’s self-perspective differs from third-party ratings, and whether or not the patients’ self-rating of social functioning is influenced by their awareness of illness. Sampling and Methods: Based on the Personal and Social Performance (PSP) scale as a clinician-administered scale, a PSP self-rating scale for patients was developed. The study included 42 inpatients with schizophrenia. Instruments were the PSP scale, the PSP self-rating scale, the Clinical Global Impression-Severity Scale, and the Scale to Assess Unawareness of Mental Disorder. Results: A significant correlation was found between PSP self- and clinician’s rating for ‘socially useful activities’, whereas the other PSP subdimensions as well as the total score were not significantly correlated. For patients with high insight, a significantly positive association emerged with ‘disturbing and aggressive behaviour’, while there was no significant correlation between PSP self- and clinician’s ratings for the patients with poor insight into their disorder. Conclusions: Patients and clinicians only marginally converge on their judgments concerning the patients’ psychosocial functioning. Patients’ insight may have a moderating role on the approximation of agreement between self- and third-party ratings. Results are discussed in line with the present literature regarding the accuracy of self-awareness in schizophrenia.

Keywords:
Personal and Social Performance self-rating scale, Personal and Social Performance scale, Schizophrenia, Psychosocial functioning
1.
Burns T, Patrick D: Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand 2007;116:403–418.
2.
Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weider PJ: Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr 2005;10:1–13.
3.
Nasrallah H, Morosini P, Gagnon DD: Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 2008;161:213–224.
4.
Bell M, Fiszdon J, Richardson R, Lysaker P, Bryson G: Are self-reports valid for schizophrenia patients with poor insight? Relationship of unawareness of illness to psychological self-report instruments. Psychiatry Res 2007;151:37–46.
5.
Niv N, Cohen AN, Mintz J, Ventura J, Young AS: The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophr Res 2007;90:245–250.
6.
Huppert JD, Smith TE, Apfeldorf WJ: Use of self-report measures of anxiety and depression in outpatients with schizophrenia: reliability and validity. J Psychopathol Behav Assess 2002;24:275–283.
7.
Dickerson FB, Ringel NB, Parente F: Ratings of social functioning in outpatients with schizophrenia: patient self-report versus caregiver assessment. Eval Program Plann 1997;20:415–420.
8.
Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S: The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry 1990;157:853–859.
9.
Becchi A, Rucci P, Placentino A, Neri G, de Girolamo G: Quality of life in patients with schizophrenia – comparison of self-report and proxy assessments. Soc Psychiatry Psychiatr Epidemiol 2004;39:397–401.
10.
Bowie CR, Twamley EW, Anderson H, Halpern B, Patterson TL, Harvey PD: Self-assessment of functional status in schizophrenia. J Psychiatr Res 2007;41:1012–1018.
11.
Lysaker PH, Roe D, Yanos PT: Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull 2007;33:192–199.
12.
Lysaker PH, Bell M, Milstein R, Bryson G, Beam-Goulet J: Insight and psychosocial treatment compliance in schizophrenia. Psychiatry 1994;57:307–315.
13.
Lysaker PH, Bryson GJ, Bell MD: Insight and work performance in schizophrenia. J Nerv Ment Dis 2002;190:142–146.
14.
Lysaker PH, Buck KD, Salvatore G, Popolo R, Dimaggio G: Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Rev Neurother 2009;9:1035–1043.
15.
Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;1001:323–329.
16.
Schaub D, Juckel G: PSP Scale: German version of the Personal and Social Performance Scale: valid instrument for the assessment of psychosocial functioning in the treatment of schizophrenia. Nervenarzt 2010, E-pub ahead of print.
17.
Juckel G, Schaub D, Fuchs N, Naumann U, Uhl I, Witthaus H, Hargarter L, Bierhoff HW, Brüne M: Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophr Res 2008;104:287–293.
18.
Schaub D, Abdel-Hamid M, Brüne M: Schizophrenia and social functioning: the role of impaired metacognition; in Dimaggio G, Lysaker PH (eds): Metacognition and Severe Adult Mental Disorders. From Research to Treatment (chapter 5). New York, Routledge, 2010, pp 83–94.
19.
Guy W: Clinical global impressions; in Guy W (ed): ECDEU Assessment Manual for Psychopharmacology. Rockville, National Institute for Mental Health, 1976, pp 218–220.
20.
Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM: The assessment of insight in psychoses. Am J Psychiatry 1993;150:873–879.
21.
Lambert M, Naber D: Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004;18:5–17.
22.
Eichenberger A, Rössler W: Comparison of self-ratings and therapist ratings of outpatients’ psychosocial status. J Nerv Ment Dis 2000;188:297–300.
23.
Drake RJ, Pickles A, Bentall RP, Kinderman P, Haddock G, Tarrier N, Lewis SW: The evolution of insight, paranoia and depression during early schizophrenia. Psychol Med 2004;34:285–292.
24.
Crumlish N, Whitty P, Kamali M, Clarke M, Browne S, McTique O, Lane A, Kinsella A, Larkin C, O’Callaghan E: Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr Scand 2005;112:449–455.
25.
Langdon R, Ward P: Taking the perspective of the other contributes to the awareness of illness in schizophrenia. Schizophr Bull 2009;35:1003–1011.
26.
Brüne M, Abdel-Hamid M, Lehmkämper C, Sonntag C: Mental state attribution, neurocognitive functioning, and psychopathology: what predicts poor social competence in schizophrenia best? Schizophr Res 2007;92:151–159.
27.
Lysaker PH, Carcione A, Dimaggio G, Johannesen JK, Nicoló G, Procacci M, Semerari A: Metacognition amidst narratives of self and illness in schizophrenia: associations with neurocognition, symptoms, insight and quality of life. Acta Psychiatr Scand 2005;112:64–71.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.